RESUMO
Absorption spectra (77 and 298 K), luminescence spectra (5-80 K), and luminescence lifetimes (5-80 K) for the title complexes have been correlated to increasing diphosphine basicity (R = 4-CF(3)-Ph < 4-H-Ph < 4-CH(3)O-Ph < Et). As a consequence, spectral peaks have been assigned to (1,3)MLCT (B(1u), W --> phosphorus) and (1,3)LF (B(2g)) terms. As the ligand basicity increases, the (3)MLCT bands observed in absorption blue-shift nearly 8000 cm(-1) and the vibrationally structured (3)LF bands observed in emission red-shift approximately 1300 cm(-1). (3)LF terms lie lowest in energy in the 4-H-Ph, 4-CH(3)O-Ph, and Et compounds, and temperature-dependent lifetime data suggest emission from each be assigned to the equilibrated, spin-orbit split levels of the (3)LF term. The (3)LF and (3)MLCT excited-state terms lie close in energy in the 4-CF(3)-Ph compound, resulting in an emission band shape that is temperature-dependent. At 77 K, the emission band is broad and structureless and is assigned to arise primarily from the (3)MLCT term. As the temperature is lowered toward 5 K, the (3)MLCT emission diminishes in intensity accompanied by the development of a vibrational structure that is characteristic of emission from the (3)LF term. These excited-state terms satisfy the requirements (different orbital origins, near-degeneracy) for separation by a Franck-Condon energy barrier, resulting in simultaneous emission from both terms between 5 and 77 K.
RESUMO
Transforming growth factor-beta (TGF-beta) isoforms have differential binding affinities for the TGF-beta type II receptor (TbetaRII). In most cells, TGF-beta1 and TGF-beta3 bind to TbetaRII with much higher affinity than TGF-beta2. Here, we report an analysis of the effect of TGF-beta structure on its binding to TbetaRII by using TGF-beta mutants with domain deletions, amino acid replacements, and isoform chimeras. Examination of the binding of TGF-beta mutants to the recombinant extracellular domain of TbetaRII by a solid-phase TGF-beta/TbetaRII assay demonstrated that only those TGF-beta mutants containing the C terminus of TGF-beta1 (TGF-beta1-(Delta69-73), TGF-beta1-(Trp71), and TGF-beta2/beta1-(83-112)) bind with high affinity to TbetaRII, similar to native TGF-beta1. Moreover, replacement of only 6 amino acids in the C terminus of TGF-beta1 with the corresponding sequence of TGF-beta2 (TGF-beta1/beta2-(91-96)) completely eliminated the high affinity binding of TGF-beta1. Proliferation of fetal bovine heart endothelial (FBHE) cells was inhibited to a similar degree by all of the TGF-beta mutants. However, recombinant soluble TbetaRII blocked the inhibition of FBHE cell proliferation induced by TGF-beta mutants retaining the C terminus of TGF-beta1, consistent with the high binding affinity between these TGF-beta molecules and TbetaRII. It was further confirmed that the TGF-beta2 mutant with its C terminus replaced by that of TGF-beta1 (TGF-beta2/beta1-(83-112)) competed as effectively as TGF-beta1 with 125I-TGF-beta1 for binding to membrane TbetaRI and TbetaRII on FBHE cells. These observations clearly indicate that the domain in TGF-beta1 responsible for its high affinity binding to TbetaRII, both the soluble and membrane-bound forms, is located at C terminus of the molecule.
Assuntos
Receptores de Fatores de Crescimento Transformadores beta/química , Fator de Crescimento Transformador beta/química , Sequência de Aminoácidos , Animais , Ligação Competitiva , Bioensaio , Bovinos , Divisão Celular , Células Cultivadas , Mapeamento de Epitopos , Humanos , Dados de Sequência Molecular , Ligação Proteica , Proteínas Serina-Treonina Quinases , Estrutura Terciária de Proteína , Receptor do Fator de Crescimento Transformador beta Tipo II , Receptores de Fatores de Crescimento Transformadores beta/metabolismo , Proteínas Recombinantes , Alinhamento de Sequência , Solubilidade , Relação Estrutura-Atividade , Fator de Crescimento Transformador beta/metabolismoRESUMO
Transforming growth factor-beta (TGF-beta) is a potent regulator of cell growth and differentiation. On the basis of the crystal structure of TGF-beta 2, we have designed and synthesized two mutant TGF-beta s, TGF-beta 1 (71 Trp) and TGF-beta 1 (delta 69-73). Although both of these molecules inhibited the growth of Mv1Lu mink lung epithelial cells and LS1034 colorectal cancer cells, which are affected equally by TGF-beta 1 and TGF-beta 2, TGF-beta 1 (delta 69-73) was much less potent than TGF-beta 1 or TGF-beta 1 (71 Trp) at inhibiting the growth of LS513 colorectal cancer cells which are growth-inhibited by TGF-beta 1 but not TGF-beta 2. Both TGF-beta 1 (71 Trp) and TGF-beta 1 (delta 69-73) increased levels of mRNAs for fibronectin and plasminogen activator inhibitor with Mv1Lu cells, whereas only TGF-beta 1 (71 Trp) and not TGF-beta 1 (delta 69-73) up-regulated the mRNA level of carcinoembryonic antigen in LS513 cells. The expression level of carcinoembryonic antigen mRNA in LS1034 cells was not altered by either wild-type or mutant TGF-beta s. Receptor labeling experiments demonstrated that TGF-beta 1 (71 Trp) bound with high affinity to the cell-surface receptors of Mv1Lu, LS1034, and LS513 cells while TGF-beta 1 (delta 69-73) bound effectively to the receptors of Mv1Lu and LS1034 cells but much less to the receptors on LS513 cells.(ABSTRACT TRUNCATED AT 250 WORDS)
